LLY

1,054.27

-0.65%↓

JNJ

209.54

-2.29%↓

ABBV

223.9

-1.64%↓

UNH

334.13

-2.12%↓

AZN

91.41

-0.2%↓

LLY

1,054.27

-0.65%↓

JNJ

209.54

-2.29%↓

ABBV

223.9

-1.64%↓

UNH

334.13

-2.12%↓

AZN

91.41

-0.2%↓

LLY

1,054.27

-0.65%↓

JNJ

209.54

-2.29%↓

ABBV

223.9

-1.64%↓

UNH

334.13

-2.12%↓

AZN

91.41

-0.2%↓

LLY

1,054.27

-0.65%↓

JNJ

209.54

-2.29%↓

ABBV

223.9

-1.64%↓

UNH

334.13

-2.12%↓

AZN

91.41

-0.2%↓

LLY

1,054.27

-0.65%↓

JNJ

209.54

-2.29%↓

ABBV

223.9

-1.64%↓

UNH

334.13

-2.12%↓

AZN

91.41

-0.2%↓

Search

Pacific Biosciences of California Inc

Closed

SectorHealthcare

2.01 -4.74

Overview

Share price change

24h

Current

Min

1.97

Max

2.13

Key metrics

By Trading Economics

Income

3.9M

-38M

Sales

-1.3M

38M

EPS

-0.12

Profit margin

-98.853

Employees

575

EBITDA

3.2M

-32M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+13.21% upside

Market Stats

By TradingEconomics

Market Cap

28M

700M

Previous open

6.75

Previous close

2.01

Technical Score

By Trading Central

Confidence

Bullish Evidence

Pacific Biosciences of California Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 gru 2025, 23:46 UTC

Market Talk

Gold Edges Higher, Aided by Fed Rate-Cut Prospects -- Market Talk

16 gru 2025, 23:38 UTC

Market Talk

Nikkei May Rise on Possible Bargain-Hunting Interest -- Market Talk

16 gru 2025, 22:35 UTC

Acquisitions, Mergers, Takeovers

Santos: Sale Delivered Cash, Reduced Future Decommissioning Exposure

16 gru 2025, 22:35 UTC

Acquisitions, Mergers, Takeovers

Santos Sold 43% Stake in Petrel Fields, 100% of Tern Fields to Eni Australia

16 gru 2025, 22:33 UTC

Acquisitions, Mergers, Takeovers

Santos: A$40M Upfront Consideration, Up to A$20M in Contingent Payments

16 gru 2025, 22:33 UTC

Acquisitions, Mergers, Takeovers

Santos Sold 43% Operated Interest in Mahalo JV to Comet Ridge

16 gru 2025, 22:32 UTC

Acquisitions, Mergers, Takeovers

Santos Divests Two Noncore Assets as Part of Portfolio Optimization

16 gru 2025, 22:25 UTC

Acquisitions, Mergers, Takeovers

Westgold's Indicative Timetable Points to Early February Completion

16 gru 2025, 22:24 UTC

Acquisitions, Mergers, Takeovers

Westgold: Divestment Aligns With Broader Corporate Strategy

16 gru 2025, 22:23 UTC

Acquisitions, Mergers, Takeovers

Westgold: Deferred Payment Based on Performance Hurdles

16 gru 2025, 22:23 UTC

Acquisitions, Mergers, Takeovers

Westgold Will Receive A$15M Cash, A$19.6M in Alicanto Shares

16 gru 2025, 22:23 UTC

Acquisitions, Mergers, Takeovers

Westgold to Receive A$30M Deferred Payment in Cash or Shares

16 gru 2025, 22:22 UTC

Acquisitions, Mergers, Takeovers

Westgold Divesting Noncore Operating Asset for A$64.6M

16 gru 2025, 22:22 UTC

Acquisitions, Mergers, Takeovers

Westgold Agrees to Sell Mt Henry-Selene Project to Alicanto Minerals

16 gru 2025, 21:53 UTC

Earnings

Lennar Misses Earnings Estimates. The Stock Is Dropping. -- Barrons.com

16 gru 2025, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

16 gru 2025, 21:33 UTC

Acquisitions, Mergers, Takeovers

Warner Preparing to Tell Shareholders to Reject Paramount Offer -- 2nd Update

16 gru 2025, 21:18 UTC

Acquisitions, Mergers, Takeovers

Warner Preparing to Tell Shareholders to Reject Paramount Offer -- Update

16 gru 2025, 21:17 UTC

Acquisitions, Mergers, Takeovers

Worthington Enterprises to Buy LSI Group for About $205M >WOR

16 gru 2025, 21:16 UTC

Earnings

Worthington Enterprises 2Q Sales $327.5M >WOR

16 gru 2025, 21:16 UTC

Earnings

Worthington Enterprises 2Q Adj EPS 65c >WOR

16 gru 2025, 21:16 UTC

Earnings

Worthington Enterprises 2Q EPS 55c >WOR

16 gru 2025, 21:15 UTC

Acquisitions, Mergers, Takeovers

Worthington Enterprises Agrees To Acquire Leading Metal Roof Components Manufacturer LSI Group >WOR

16 gru 2025, 21:05 UTC

Acquisitions, Mergers, Takeovers

Ecolab Closes Acquisition Of Ovivo's Electronics Ultrapure Water Business >ECL

16 gru 2025, 20:54 UTC

Acquisitions, Mergers, Takeovers

Warner to Reject Paramount Offer As Soon As Wednesday, Sources Say -- WSJ

16 gru 2025, 20:54 UTC

Acquisitions, Mergers, Takeovers

Warner Preparing to Tell Shareholders to Reject Paramount Offer -- WSJ

16 gru 2025, 20:54 UTC

Acquisitions, Mergers, Takeovers

Warner to Recommend Existing Netflix Deal, Sources Say -- WSJ

16 gru 2025, 20:44 UTC

Market Talk

Russia-Ukraine Peace Efforts Send Crude to Near 5-Year Low -- Market Talk

16 gru 2025, 20:04 UTC

Market Talk

U.S. Natural Gas Extends Weather-Driven Losing Streak -- Market Talk

16 gru 2025, 20:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer Comparison

Price change

Pacific Biosciences of California Inc Forecast

Price Target

By TipRanks

13.21% upside

12 Months Forecast

Average 2.4 USD  13.21%

High 3 USD

Low 2 USD

Based on 5 Wall Street analysts offering 12 month price targets forPacific Biosciences of California Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

3

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

1.13 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat